NOVO — December 2025
-
Deep Value Investing
@DeepIceValue$NVO has slashed Wegovy prices in India nearly 40%. This move has dramatically increased sales volume by 70% in November. The drug's market share also rose 14%.
This price reduction aims to compete with rival Mounjaro..
Another $NVO drug, Ozempic, is expected to launch soon, potentially further impacting the prices..
-
Novo Nordisk has completed its acquisition of Akero Therapeutics https://ml-eu.globenewswire.com/Resource/Download/ef5d46b2-5731-42ce-9ac9-8dc2c75ffc26
-
Novo Nordisk overtager endeligt Akero https://proinvestor.com/investornyt/1391512/novo-nordisk-overtager-endeligt-akero
-
Fra Børsen "Nye tendenser i markedet for vægttabsmedicin løfter værdien en anelse frem mod 2030, vurderer storbanken Goldman Sachs i en ny analyse.
Banken vurderer, at markedet i 2030 vil have en værdi på 102 mia. dollar, hvor vurderingen tidligere lød på 95 mia. dollar.
Den højere vurdering kommer i kølvandet af, at Novo Nordisk og Eli Lilly har varslet lavere priser på vægttabsmedicin i USA, men analytikerne vurderer, at prisfaldet vil blive opvejet af stigende salgsvolumener."
-
Pfizer øger satsning på vægtbehandling med licensaftale til 2,1 mia. dollar https://proinvestor.com/investornyt/1391839/pfizer-oger-satsning-pa-vaegtbehandling-med-licensaftale-til-21-mia-dollar
-
Nyheder fra danske medier med Novo Nordisk, Nemlig.com og Axcel https://proinvestor.com/investornyt/1391834/nyheder-fra-danske-medier-med-novo-nordisk-nemligcom-og-axcel
-
Novo har skabt en revolution. Og den er klar til salgskanalerne
Slankemedicin fra Novo Nordisk og konkurrenten Eli Lilly baner vejen for en ny måde at sælge medicin på på lægemiddelindustriens hovedmarked i USA.
Finans (finans.dk)
-
HSBC har set lyset "Novo Nordisk (+0,1%, 299,20 kr.) får sat kursmålet op til 350 kr. fra før 300 kr. - og det nye kursmål indikerer et potentiale på 17 pct. i forhold til den nuværende kurs. Anbefalingen "hold" gentages. Det fremgår af data fra Bloomberg News. "
-
Novo: Hims & Hers udvider med vægttabsmidler i Storbritannien https://proinvestor.com/investornyt/1391874/novo-hims-hers-udvider-med-vaegttabsmidler-i-storbritannien
-
FED sænker sandsynligvis renten - hvad nu? Vi ser på Genmabs data, Bavarians vigtige investormøde og Zealands store pengetank. Kan Wegovy-pillen og aktietilbagekøb vende stemningen i Novo Nordisk? Få svar på det og meget mere i afsnit 301 af Investeringspodcasten. https://proinvestor.com/boards/130232
-
Oral Wegovy - The Catalyst Novo Nordisk Needs?
Oral Wegovy vs Orforglipron. Who wins? https://tacticzhazel.substack.com/p/oral-wegovy-the-catalyst-novo-nordisk?utm_source=activity_item -
WARNING: This Bill Will End Compounded GLP-1 As We Know It https://www.youtube.com/watch?v=ptVV-f8zUp4
-
Looming GLP-1 drug patent expirations draw generics firms
India and China are among the countries where knockoffs of Wegovy and Ozempic can be sold next year https://cen.acs.org/pharmaceuticals/Looming-GLP-1-drug-patent/103/web/2025/12?sc=251210_sc_eng_fb_cen
-
Det er et godt bud Pauly. Hims & Hers falder derimod i dag 4% og tæt på det samme i går..
-
Godmorgen
-
Hims stock falls after lawmakers propose GLP-1 compounding restrictions
Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.
Yahoo Finance (finance.yahoo.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind